Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Evotec SE
  6. News
  7. Summary
    EVT   DE0005664809


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Evotec AG : Evotec and The Leukemia & Lymphoma Society enter into a strategic research collaboration

11/05/2013 | 04:01am EDT

Hamburg, Germany - 05 November 2013: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that it has entered into an integrated research collaboration with The Leukemia & Lymphoma Society ('LLS'). Evotec will support one of LLS's Screen-to-Lead Programs ('SLP'). In this collaboration, Evotec partners with LLS to support selected programmes and principal investigators with resources for high-throughput screening and optimisation of small molecules into drug-like compounds. Evotec delivers an industrialised, cutting-edge, comprehensive and unbiased drug discovery infrastructure to support innovation efficiency as part of a fully integrated solution.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: 'We are excited to initiate this collaboration and support The Leukemia and Lymphoma Society and their investigators. We are confident that our experienced scientists and innovation platform can deliver results for LLS, their investigators and ultimately patients.'

Amy Burd, Ph.D., Executive Director of Research at LLS, added: 'LLS is pleased to be working in collaboration with Evotec to advance our Screen-to-Lead programs. We feel that Evotec has the necessary skills and capabilities to offer significant value to support these projects.'

No financial details were disclosed.

The Leukemia & Lymphoma Society (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, multiple myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

FORWARD LOOKING STATEMENTS - Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

(pdf - 73,23 kB)
distributed by

© Publicnow 2013
All news about EVOTEC SE
01:32aPRESS RELEASE  : Evotec launches 'beLAB1407' to -2-
01:32aPRESS RELEASE  : Evotec launches 'beLAB1407' to accelerate translational researc..
01:32aEVOTEC  : launches 'beLAB1407' to accelerate translational research from the UK'..
05/04EVOTEC  : to announce results for the first quarter 2021 on 11 May 2021
05/04EVOTEC  : to announce results for the first quarter 2021 on 11 May 2021
05/04PRESS RELEASE  : Evotec SE to announce results for the first quarter 2021 on 11 ..
05/04EVOTEC  : and the GCKD study enter into strategic collaboration to build a uniqu..
05/04PRESS RELEASE : Evotec and the GCKD study enter into strategic collaboration to ..
05/04EVOTEC  : and the GCKD study enter into strategic collaboration to build a uniqu..
04/30EVOTEC SE : Release according to Article 41 of the WpHG [the German Securities T..
More news
Sales 2021 560 M 674 M 674 M
Net income 2021 34,6 M 41,7 M 41,7 M
Net cash 2021 40,0 M 48,2 M 48,2 M
P/E ratio 2021 162x
Yield 2021 -
Capitalization 5 624 M 6 749 M 6 771 M
EV / Sales 2021 9,98x
EV / Sales 2022 8,59x
Nbr of Employees 3 572
Free-Float 85,5%
Duration : Period :
Evotec SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 33,39 €
Last Close Price 34,36 €
Spread / Highest target 6,23%
Spread / Average Target -2,83%
Spread / Lowest Target -14,1%
EPS Revisions
Managers and Directors
Werner Lanthaler Chief Executive Officer
Enno Spillner Chief Financial Officer
Wolfgang Plischke Chairman-Supervisory Board
Cord E. Dohrmann Chief Scientific Officer
Craig L. Johnstone Chief Operating Officer & Member-Management Board
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC SE13.47%6 749
MODERNA, INC.55.87%65 222
LONZA GROUP AG2.85%47 572
CELLTRION, INC.-27.58%31 514
SEAGEN INC.-22.87%24 514